Baseline characteristics of patients in the included studies.
| Study ID | Trial | Gender (male %; intervention/placebo) | Mean age ± SD or median (IQR); (intervention/placebo) | Patients receiving background HCM therapy (intervention/placebo; number of patients) | NYHA class (intervention/placebo; number of patients) | Baseline resting LVOT gradient (mmHg; intervention/placebo), mean (SD) | Baseline LVEF (%);mean (SD);(intervention/placebo) | ||
|---|---|---|---|---|---|---|---|---|---|
| Beta-blocker | Calcium channel blocker | II | III | ||||||
| Mavacamten | |||||||||
| Olivotto et al. 2020 [10] | EXPLORER-HCM | 54/65 | 58.5 ± 12.2/58.5 ± 11.8 | 94/95 | 25/17 | 88/95 | 35/33 | 52 (29)/51 (32) | 74 (6)/74 (6) |
| Ho et al. 2020 [6] | MAVERICK-HCM | 47.5/31.6 | 54 ± 14.6/53.8 ± 18.2 | 25/12 | 10/3 | 33/13 | 7/6 | - | 68.7 (5.5)/66.4 (7.7) |
| Desai et al. 2022 [8] | VALOR-HCM | 51.8/50.0 | 59.8 ± 14.2/60.9 ± 10.5 | 26/25 | 7/10 | 4/4 | 52/52 | 51.2 (31.4)/46.3 (30.5) | 67.9 (3.7)/68.3 (3.2) |
| Tian et al. 2023 [9] | EXPLORER-CN | 75.9/63.0 | 52.4 ± 12.1/51.0 ± 11.8 | 48/24 | 4/2 | 44/18 | 10/9 | 74.6 (35.1)/73.4 (32.2) [peak resting LVOT gradient] | 77.8 (6.9)/77.0 (6.7) |
| Aficamten | |||||||||
| Maron et al. 2023 [11] | REDWOOD-HCM | 46/38 | 57 (26–33)/59 (53–64) [median (IQR)] | 21/11 | 7/2 | 17/11 | 11/2 | 53 (42–70)/71 (44–94) [median (IQR)] | 70 (65-79)/75 (69-75) [median (IQR)] |
| Maron et al. 2024 [7] | SEQUOIA-HCM | 60.6/57.9 | 59.2 ± 12.6/59.0 ± 13.3 | 86/87 | 45/36 | 108/106 | 34/33 | 54.8 (27.0)/55.3 (32.1) | 74.8 (5.5)/74.8 (6.3) |
HCM: hypertrophic cardiomyopathy; NYHA: New York Heart Association; IQR: inter-quartile range; LVOT: left ventricular outflow tract; LVEF: left ventricular ejection fraction. -: data not available.